Vanda Pharmaceuticals (VNDA) Tops Q1 EPS by 7c

Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q1 EPS of ($0.17), $0.07 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $33.3 million versus the consensus estimate of $32.57 million.

2016 Financial Guidance

Vanda reiterates its prior 2016 financial guidance and expects to achieve the following financial objectives in 2016:

• Combined net product sales from both HETLIOZ® and Fanapt® of between $143 and $153 million.
• HETLIOZ® net product sales of between $73 and $78 million and Fanapt® net product sales of between $70 and $75 million.
• Non-GAAP Operating expenses, excluding Cost of goods sold, of between $125 and $135 million.
• Non-GAAP Operating expenses excludes intangible asset amortization expense of $10.9 million and stock-based compensation of between $9 and $11 million.
• Year end 2016 Cash is expected to be between $123 and $143 million.

For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.

You May Also Be Interested In

• Delta Air Lines (DAL) Misses Q3 EPS by 20c, Beats on Revenue; Cuts FY EPS Guidance
• Top AI Semiconductor Stocks According to Stifel Analysis
• Aritzia (ATZ:CN) (ATZAF) PT Raised to Cdn$228 at UBS on Strong Growth